The review will evaluate data from preclinical and clinical studies of NVX-CoV2373 to expedite the vaccine’s marketing authorisation approval later.
List view / Grid view
Filter the results
Novavax’s NVX-CoV2373 vaccine candidate was 89.3 percent effective overall and 85.6 percent effective against the B.1.1.7 SARS-CoV-2 variant, in a Phase III trial.
Reports have said five people have been killed in a fire at the Serum Institute of India, where the Oxford-AstraZeneca COVID-19 vaccine is being made.
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
The agreement is expected to advance the commercial-scale manufacturing of the NVX-CoV2373 to enable it to be distributed across Europe following regulatory approval.
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.
As the race to develop a COVID-19 vaccine intensifies, nations are already ramping up production capacity on a scale never seen before – but what does this mean for manufacturers? Here, Rod Schregardus makes the case for advanced planning and scheduling techniques in new and existing facilities.
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
Nine biopharma CEOs pledged to make the integrity of the scientific process and sufficient supply priorities in the development of COVID-19 vaccines.
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
The Phase II clinical trial to study NVX-CoV2373, the Novavax COVID-19 vaccine candidate, has enrolled its first patient.
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.